Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: A prospective evaluation

Yoshinobu Kanda, Shin Mineishi, Takeshi Saito, Akiko Saito, Mutsuko Ohnishi, Hironari Niiya, Aki Chizuka, Kunihisa Nakai, Toshio Takeuchi, Hiroshi Matsubara, Atsushi Makimoto, Ryuji Tanosaki, Hideo Kunitoh, Kensei Tobinai, Yoichi Takaue

研究成果: Article

50 引用 (Scopus)

抜粋

Background. Preemptive therapy against cytomegalovirus (CMV) disease has succeeded in reducing the incidence of CMV disease, but the toxicity of ganciclovir remains problematic. Methods. We prospectively evaluated the efficacy and toxicity of a preemptive protocol with ganciclovir at a reduced initial dose in 40 patients who achieved engraftment after allogeneic hematopoietic stem cell transplantation. Results. Twenty-three (58%) patients had high-risk features, including transplant from an HLA-mismatched or unrelated donor, or associated acute graft-versus-host disease. CMV antigenemia assay was performed weekly, and ganciclovir was started in a risk-adapted manner, in which the initial dose of ganciclovir was fixed at 5 mg/kg/d and then adjusted based on the results of a weekly CMV antigenemia assay. In this protocol, 23 (58%) patients demonstrated positive antigenemia, and 19 (48%) received a preemptive administration of ganciclovir. Only one patient had CMV disease in the gastrointestinal system, which was successfully treated with a regular therapeutic dose of ganciclovir. Consequently, the total dose of ganciclovir was significantly less than that in a previous protocol using the conventional double dose (5 mg/kg twice daily) of ganciclovir (134 mg/kg vs. 190 mg/kg on average, P=0.046). There were no significant toxicities attributed to ganciclovir, except for neutropenia <0.5 × 109/L, which developed in three patients for 3, 4, and 14 days, respectively, with granulocyte colony-stimulating factor support. Conclusion. Preemptive therapy with a low initial dose of ganciclovir appeared to be effective even in high-risk patients. Further randomized controlled trial is warranted.

元の言語English
ページ(範囲)568-572
ページ数5
ジャーナルTransplantation
73
発行部数4
DOI
出版物ステータスPublished - 2002 2 27
外部発表Yes

ASJC Scopus subject areas

  • Transplantation

フィンガープリント Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: A prospective evaluation' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Kanda, Y., Mineishi, S., Saito, T., Saito, A., Ohnishi, M., Niiya, H., Chizuka, A., Nakai, K., Takeuchi, T., Matsubara, H., Makimoto, A., Tanosaki, R., Kunitoh, H., Tobinai, K., & Takaue, Y. (2002). Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: A prospective evaluation. Transplantation, 73(4), 568-572. https://doi.org/10.1097/00007890-200202270-00015